Astragalin, a flavonoid compound found in various plants such as Polygonum aviculare, Moringa oleifera, and Camellia sinensis, has been investigated for its hepatoprotective properties in preclinical studies. Research primarily conducted in vitro and in animal models has indicated that astragalin exhibits antioxidant and anti-inflammatory effects, which may offer protection against liver injury, including hepatitis induced by toxins or viruses. For example, studies have demonstrated that astragalin can decrease markers of oxidative stress and inflammatory cytokines in rodent models of chemically-induced hepatitis (Liu et al., 2016).

However, the evidence is limited to basic and preclinical research; there are no published clinical trials in humans evaluating astragalin’s efficacy or safety for treating hepatitis of any cause. The underlying mechanisms proposed include inhibition of pro-inflammatory pathways (such as NF-κB) and reduction of hepatocyte apoptosis. These mechanistic insights are promising but not yet validated in human populations.

In summary, while there is some scientific rationale and preliminary experimental evidence suggesting astragalin could have hepatoprotective effects relevant to hepatitis, the level of evidence is weak (rated 2/5), and there is no clinical validation. As such, astragalin should not be considered a proven or established treatment for hepatitis in humans at this time.